Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC Hires Experienced Pharmaceutical Manager and Oncology Expert

Published: Friday, July 04, 2014
Last Updated: Friday, July 04, 2014
Bookmark and Share
Dr Erich Enghofer joins 4SC in the newly created position of Executive Vice President.

4SC AG has announced that Dr Erich Enghofer has joined 4SC in June 2014 in the newly created position of Executive Vice President Oncology and Haematology thus further strengthening the company's expertise.

The highly experienced pharma manager and oncology expert will primarily advance the strategic marketing of 4SC's main product resminostat in its further development toward market approval in the liver cancer indication.

In this connection, Dr Enghofer will further strengthen 4SC's positioning and products vis-à-vis potential pharmaceutical partners, strategic and clinical opinion leaders and investors, and also support the company in its partnering activities in the field of business development.

Dr Enghofer has more than 30 years of experience in the pharmaceutical industry with a focus on oncology, during which he held various management and executive positions at Bayer, Medac Schering Onkologie, Amgen, Cyanamid-Lederle and Klinge Pharma (now Astellas).

For the last nine years, he was head of the Business Unit Oncology (Haematology-Oncology since 2011) at Bayer HealthCare Deutschland in Leverkusen until May 2014. In this function, he was instrumental, among other things, in the attainment of market approval of the small molecule anti-cancer drug sorafenib (Nexavar®) in the liver cancer indication and the drug's market success in Germany.

Dr Enghofer was a Board member of Deutsche Krebsgesellschaft (DKG, the German Cancer Society) until May 2014 and is a member of various high-profile professional organizations such as the German Association for Haematology and Oncology (DGHO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH) and the American Association for the Advancement of Science (AAAS).

Enno Spillner, CEO of 4SC AG, commented: "We are delighted to have Dr Erich Enghofer, an experienced pharmaceutical manager, joining 4SC. His vast expertise in the field of oncology, especially with the drug sorafenib for treating liver cancer, will further strengthen our team and is most welcome - especially for positioning our compound resminostat as a new potential liver cancer therapy and in our ongoing preparations for a Phase II trial in this indication. Dr Enghofer will also provide crucial support to 4SC in the expansion of a partner network to key opinion leaders and pharmaceutical companies, as well as in the business development process."

Dr Erich Enghofer commented: "I am very much looking forward to working in such a dynamic biotechnology company as 4SC, which has developed a promising and innovative approach for the liver cancer indication with resminostat. I have been following the company's activities and product developments, especially resminostat, for several years now. Liver cancer is the fifth most common type of cancer worldwide and the third most frequent tumour-related cause of death. The number of new cases has been rising sharply over the recent years, giving rise to a high unmet medical need. My goal is to make a contribution to attaining market approval for resminostat so as to make it available for patients as quickly as possible."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Strengthens Patent Protection for its Epigenetic Cancer Drug Candidate 4SC-202
A selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China.
Tuesday, August 18, 2015
4SC's Partner Yakult Honsha Starts Clinical Phase I Study in Pancreatic Tract Cancer Patients
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various dosing schemes in order to determine dose regimen for potential subsequent Phase II trials in advanced pancreatic and/or biliary tract cancer.
Friday, June 26, 2015
4SC Presents Final Results from Phase I AEGIS Trial at ASCO
Daily dosage of oral, anti-mitotic Eg5 inhibitor shows good safety and tolerability.
Thursday, June 04, 2015
BEYOND RESEARCH Initiative of 4SC Discovery and CRELUX Reaches First Milestone
Compounds for inhibiting oxygen radicals and associated signalling pathways optimized for developing innovative therapies for degenerative diseases.
Tuesday, January 13, 2015
4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205
4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucial role in cell division and tumour growth.
Friday, December 12, 2014
4SC's Partner Yakult Honsha Completes Phase I Part of Clinical Study with Resminostat in NSCLC Patients
Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian NSCLC patients.
Saturday, October 11, 2014
CRELUX and 4SC Discovery Awarded Research Grant
Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme.
Thursday, July 24, 2014
4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study
Company will present data from Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO.
Friday, May 30, 2014
4SC Discovery Receives EU Grant Worth EUR 450,000
Three-year research collaboration with the Medical Clinic of the University of Munich includes a project for identification and optimization of new compounds against a novel epigenetic target molecule.
Thursday, April 17, 2014
4SC Discovery Collaborates with Heidelberg University Hospital
The two-year R&D project is aimed at delivering a lead compound that can be brought to clinical development with the help of potential partners.
Friday, March 21, 2014
4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
4SC's Partner Yakult Honsha Starts Clinical Phase I/II Study with Resminostat in NSCLC
The Phase I/II study will investigate safety and efficacy of resminostat/docetaxel combination vs. docetaxel alone as a novel treatment option for patients with advanced, metastatic, or recurrent NSCLC.
Thursday, July 25, 2013
4SC Expands Patent Protection for Epigenetic Anti-Cancer Compound
4SC AG announced that the company has significantly expanded international patent protection for 4SC-202 in the USA, China and Hong Kong.
Monday, July 15, 2013
4SC Gives Update on the Clinical Development of its Lead Cancer Compound Resminostat
Data from completed Phase I part of SHORE study confirms the safety of the resminostat FOLFIRI combination and showing encouraging signs of clinical benefit
Thursday, May 30, 2013
4SC Reports Positive Data from Clinical Phase I trial with 4SC-205 in Cancer Patients
All primary objectives of the clinical study achieved.
Thursday, March 28, 2013
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!